FTO enhances leukemogenesis and leukemia oncogene-mediated cell transformation by reducing m6A levels on mRNA transcripts of targets such as ASB2 and RARA, thereby regulating their expression and inhibiting all-trans retinoic acid (ATRA)-induced differentiation of AML cells. The gene discussed is RARA; the disease is acute myeloid leukemia.